The APERITIF trial evaluated the efficacy of adding very low-dose rivaroxaban (2.5 mg twice daily) to dual antiplatelet therapy (DAPT) for the prevention of left ventricular (LV) thrombus in patients following anterior ST-segment elevation myocardial infarction (STEMI).
Primary results showed that LV thrombus occurred in 13.7% of the rivaroxaban group compared to 16.6% in the DAPT-only group, a difference that was not statistically significant (P = .34).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
